Back

XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against emerging SARS-CoV-2 variants

Wang, Q.; Guo, Y.; Bowen, A.; Mellis, I. A.; Valdez, R.; Gherasim, C.; Gordon, A.; Liu, L.; Ho, D. D.

2023-11-27 immunology Community evaluation
10.1101/2023.11.26.568730 bioRxiv
Show abstract

COVID-19 vaccines have recently been updated with the spike protein of SARS-CoV-2 XBB.1.5 subvariant alone, but their immunogenicity in humans has yet to be fully evaluated and reported, particularly against emergent viruses that are rapidly expanding. We now report that administration of an updated monovalent mRNA vaccine (XBB.1.5 MV) to uninfected individuals boosted serum virus-neutralization antibodies significantly against not only XBB.1.5 (27.0-fold) and the currently dominant EG.5.1 (27.6-fold) but also key emergent viruses like HV.1, HK.3, JD.1.1, and JN.1 (13.3-to-27.4-fold). In individuals previously infected by an Omicron subvariant, serum neutralizing titers were boosted to highest levels (1,504-to-22,978) against all viral variants tested. While immunological imprinting was still evident with the updated vaccines, it was not nearly as severe as the previously authorized bivalent BA.5 vaccine. Our findings strongly support the official recommendation to widely apply the updated COVID-19 vaccines to further protect the public.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
Nature Communications
○ 5641 papers in training set
Top 13%
14.5%
Similar papers in this journal
2
Nature
○ 645 papers in training set
Top 1%
12.2%
Similar papers in this journal
3
Nature Medicine
○ 125 papers in training set
Top 0.1%
9.3%
Similar papers in this journal
4
Cell
○ 431 papers in training set
Top 2%
4.2%
Similar papers in this journal
5
Med
○ 39 papers in training set
Top 0.1%
4.2%
Similar papers in this journal
6
Nature Immunology
○ 79 papers in training set
Top 0.8%
3.4%
7
Cell Reports Medicine
○ 153 papers in training set
Top 0.8%
3.3%
50% of probability mass above
8
eLife
● 5828 papers in training set
Top 38%
3.1%
9
The Lancet Infectious Diseases
○ 73 papers in training set
Top 0.3%
3.1%
10
npj Vaccines
○ 67 papers in training set
Top 0.3%
3.1%
11
eBioMedicine
○ 183 papers in training set
Top 1%
3.1%
12
Cell Reports
○ 1498 papers in training set
Top 13%
3.1%
13
Science Translational Medicine
● 127 papers in training set
Top 1%
2.4%
14
Proceedings of the National Academy of Sciences
● 2444 papers in training set
Top 23%
2.3%
15
Immunity
○ 67 papers in training set
Top 0.9%
2.0%
16
Science Immunology
● 88 papers in training set
Top 1%
1.9%
17
Science
● 477 papers in training set
Top 5%
1.7%
18
Gut
● 40 papers in training set
Top 0.5%
1.7%
19
Frontiers in Immunology
○ 638 papers in training set
Top 6%
1.6%
20
Nature Microbiology
○ 155 papers in training set
Top 2%
1.3%
21
Cell Discovery
○ 57 papers in training set
Top 0.8%
1.1%
22
Science Advances
● 1243 papers in training set
Top 27%
1.1%
23
Cancer Cell
○ 42 papers in training set
Top 1%
1.1%
24
mBio
● 833 papers in training set
Top 10%
1.0%
25
iScience
○ 1154 papers in training set
Top 33%
1.0%
26
JAMA Network Open
● 130 papers in training set
Top 5%
0.6%
27
Cell Host & Microbe
126 papers in training set
Top 3%
0.6%
28
PNAS Nexus
◐ 159 papers in training set
Top 5%
0.6%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.